Antibodies from women immunized with Gardasil® cross-neutralize HPV 45 pseudovirions

Human Vaccines

Volumn 3, Issue 4, 2007, Pages 109-115

  Smith, Judith F ^a   Brownlow, Michelle ^a   Brown, Martha ^a   Kowalski, Rose ^a   Esser, Mark T ^a   Ruiz, Wanda ^a   Barr, Eliav ^a   Brown, Darron R ^b   Bryan, Janine T ^a,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b INDIANA UNIVERSITY   (United States)

^c WP16 100K ^*  (United States)

Author keywords

Cross neutralization; Gardasil ; HPV 45; HPV vaccine; Immune response

Indexed keywords

WART VIRUS VACCINE;

ADULT; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNIZATION; LOW DRUG DOSE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LIKE AGENT; WART VIRUS;

EID: 34548252714     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.4.4058     Document Type: Article

References (35)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-65.
2. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr 2003; 3-13.
3. Chua KL, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996; 77:121-7.
4. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Narl Cancer Inst 2005; 97:1072-9.
5. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-51.
6. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ, Hurni WM, Joyce JG, Lehman ED, Markus HZ, Neeper MP, Schultz LD, Shaw AR, Jansen KU. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. Journal of Infectious Diseases 1997; 176:1141-5.
7. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 2004; 364(9447):1757-65.
8. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah A, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multicentre phase 11 efficacy trial. Lancet Onc 2005; 6:271-8.
9. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade AP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006; 7:27-8.
10. Stanley MA. Human papillomavirus vaccines. Current Opinion in Mol Therapeutics 2002; 4:15-22.
11. Stanley MA. Immune response to human papillomavirus. Vaccine 2006; 24:S16-22, (Review).
12. Suzich JA, Ghim SJ, Paler-Hill FJ, White WI, Tamura JK, Bell JA, Newsome JA, Jenon AB, Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. PNAS 1995; 92:11553-7.
13. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller AT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci 1992; 89:12180-4.
14. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissman L, Lowy DR, Schiller JT. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993; 67:6929-36.
15. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly for HPV virion-like particles. Virology 1991; 185:251-27.
16. Christensen ND, Höpfl R, DiAngelo SL, Cladel NM, Patrick SD, Welsh PA, Budgeon LR, Reed CA, Kreider JW. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titers of neutralizing antibodies. Journal of General Virology 1994; 75:2271-6.
17. Rose RC, Reichman RC, Bonnez W. Human papillomavirus type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75:2075-9.
18. Jansen KU, Rosolowsky M, Schultz LD, Markus HZ, Cook JC. Donnelly JJ, Martinez D, Ellis RW, Shaw AR. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbirs from CRPV-inductd papilloma formation. Vaccine 1995; 13:1509-14.
19. Breitburd F, Kirnbauer R, Hubbert NL, Schiller JT, Orth G. Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-63.
20. Bernard HU. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol 2005; 32:S1-6.
21. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 2004; 324:17-24.
22. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Immunological analysis of human papillomavirus capsids. Vaccine 2001; 19:1783-1793.
23. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ,Alvarez FB, Bautista OM, Jansen KU, Barr E. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol 2006; 107:18-27.
24. Ault K, Giuliano AR, Edwards R, Tamms G, Kim LL, Smith JF, Jansen KU, Allende M, Taddeo FJ, Skulsky D, Barr E. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP viccine. Vaccine 2004; 24:5571-83.
25. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16 and 18 by multiplexed Luminex assay. Clin and Diag Lab Imm 2003; 10:108-15.
26. Dias D, VanDoren J, Schlottmanns, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. Optimization and validation of a multiplex Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16 and 18. Clin and Diag Lab Imm 2005; 12:959-69.
27. Christensen ND, Krieder JW, Cladel NM, Patrick SD, Welsh PA. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 1990; 64:5678-81.
28. Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Galloway DA. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virol 1996; 223:174-84.
29. Christensen ND, Kirnbauer R, Schiller JT, Ghim SJ, Schlegel R, Jenson AB, Kreider JW. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virol 1994; 205:329-35.
30. Hofmann KJ, Neeper MP, Markus HZ, Brown DR, Muller M, Jansen KU. Sequence conservation within the major capsid protein of human papillomavirus (HPV) type 18 and formation of HPV-18 virus-like particles in Saccharomyces cerevisiae. J Gen Virol 1996; 77:465-8.
31. Hofmann KJ, Cook JC, Joyce JG, Brown DR, Schultz LD, George HA, Rosolowsky M, Fife KH, Jansen KU. Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virol 1995; 209:506-18.
32. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, Fitzgerald PC, Kruger Kjaer S, Lowry DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV 16 and HPV 18. Virol 2004; 321:205-16.
33. Buck CB, Pastrana DV, Lowry DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol 2004; 78:751-7.
34. Combita AL, Bravo MM, Touze A, Orozco O, Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 38 and 59 virus-like particles in Colombian women with invasive cervical cancer. Int J Cancer 2002; 97:796-803.
35. White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998; 72:959-64.